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ABSTRACT 
 
Background: Tuberculosis is an infectious disease that poses serious threat to population health 
worldwide. Tuberculosis control enterprise becomes more complicated due to increasing number 
of Multi Drug Resistant Tuberkulosis (MDR-TB) cases. Globally there are approximately 580,000 
cases of  MDR-TB, with only 125,000 cases (20%) resolved. Indonesia ranks tenth in the world by 
the number of MDR-TB cases after Angola, Azerbaijan, Bangladesh, Belarus, Cina, Korea, Kongo, 
Etiopia, and India. This study aimed to analyzed the bio-psychosocial determinants of MDR-TB in 
Surakarta. 
Subjects and Method: This was an analytic observational study with case control design. The 
study was conducted in Dr. Moewardi Hospital and BBKPM, Surakarta, from September to 
November 2017. A sample consisting of 76 MDR-TB patients and 228 non MDR-TB patients were 
selected for this study by fixed disease sampling. The dependent variable was MDR-TB. The 
independent variables were age, drug-taking adherence, depression, comorbidity, drug side-effect, 
drug-taking supervisor, and family income. The data were collected using a set of questionnaire 
and analyzed by path analysis.  
Results: MDR-TB was affected by lack of drug-taking adherence (b= -1.7; 95% CI= -2.23 to -1.07; 
p=0.001) and comorbidity (b= 1.5; 95% CI= 0.76 to 2.30; p=0.001). Drug-taking adherence was 
affected by depression (b= -1.7; 95% CI= -2.60 to -0.79; p=0.001), drug side effect (b= -1.5; CI 
95%= -2.10 to -0.86; p=0.001), and drug-taking supervisor (b=2.5; 95% CI= 1.84 to 3.06; 
p=0.001). Comorbidity was affected by age (b= 0.86; 95% CI= 0.12 to 1.61; p= 0.022). 
Conclusion: MDR-TB is directly affected by lack of drug-taking adherence and comorbidity. 
MDR-TB is indirectly affected by drug-taking supervisor, depression, and drug side effect.  
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BACKGROUND 
Tuberculosis (TB) is one of the infectious 
diseases as the most leading to death in 
cases of tuberculosis with HIV comorbidi-
ties (Falzon et al., 2013). Tuberculosis is 
among the top 10 diseases causing death in 
the world with 1.4 million deaths annually 
(Petruccioli et al., 2016). The highest case 
of tuberculosis in 2015 comes from 
Southeast Asia (45.6%) of the world's 
population, and Indonesia ranks 2 out of 11 
countries after India (23%) with the 
percentage of 10%, namely 1020 cases per 
1000 population with the highest burden of 
tuberculosis (WHO, 2016a). 
Another fundamental issue other than 
the case of death is the economic problem. 
The decrease in productivity in patients 
becomes a problem that needs to be 
considered. The high cases of tuberculosis 
and the emergence of economic problems 
are becoming public health problems in the 
world especially in developing countries 
including Indonesia (Sulistiyani et al., 
2015).  
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High tuberculosis cases are difficult to 
detect and reduce, it is due to the medical 
and non-medical problems, which include 
medical problems such as the nature of 
tuberculosis as a chronic disease, in-
adequate use of anti-tuberculosis (OAT) 
drugs, immunodepression, age ≥35 years, 
diabetes mellitus and the occurrence of 
ESO, whereas non-medical problems 
include poverty, low education, low support 
of PMO and delayed diagnosis (Zhang et al., 
2016). Amita and Pratima (2008) explain 
that genetic factors, incomplid treatment 
and treatment adherence, microbiology, 
clinical factors, HIV / AIDS, programs and 
germs affect MDR-TB (Hirpa et al., 2013). 
WHO recommends Isoniazid and 
rifampicin as effective drugs for the first-
line treatment. Therefore, resistance to 
both drugs has become a serious threat 
(Mekonnen et al., 2015). WHO (2017) 
mentions in the handling of MDR-TB 
sustained crisis detection. Globally, 
580,000 cases of tuberculosis have MDR-
TB, with 125,000 (20%) cases were 
resolved. Indonesia was one of the worst 
crisis in the world and ranked tenth in the 
world (WHO, 2016b). 45% of the cases of 
detectable and potentiated MDR-TB 
needed to improve tuberculosis detection 
and early identification of MDR-TB as key 
to solve the problem (Prosser et al., 2016). 
Data on MDR-TB cases in Indonesia 
in 2015 display that there were 15.380 
cases, 1,860 confirmed cases and 1,566 
cases treated. 17 provinces in Indonesia 
have success rate of tuberculosis treatment 
<85%, one of them is Central Java Province 
(Ministry of Health, 2016). The case of 
tuberculosis in Surakarta was in the third 
highest in Central Java Province with case 
notification rate (CNR) in 2016 of 85 per 
100,000 population (Central Java 
Provincial Health Office, 2016). Based on 
preliminary study, in 2015, MDR-TB clinic 
visit reached 1839. In 2016, it reached 1793 
and in 2017 it reached 1466 visit (period of 
January-May). The number of visits in 2017 
was likely to  increase again until the 
December period. In addition to the pre-
liminary study results in BBKPM Surakarta, 
the data about treatment for 189 patients 
were found out. 
WHO recommends Directly Observed 
Treatment Shortcourse (DOTS) strategy as 
an effort to manage MDR-TB able to give 
hope for the success of MDR-TB case 
treatment (Abubakar et al., 2013). On time 
diagnosis of MDR-TB, particularly among 
new tuberculosis cases, is important to 
facilitate appropriate treatment, thus 
preventing the emergence of advanced drug 
resistance and its spread in the population 
(Atre, 2015). 
The high prevalence of MDR-TB 
indicates that the problem is an urgent that 
must be resolved by using an approach 
model capable of assessing various factors, 
either directly or indirectly. This study used 
a biopsychosocial model approach to assess 
the determinants based on causation and 
risk factors for MDR-TB both biologically, 
psychologically and socially.  
Based on the background, the author 
was interested to analyze Biopsychosocial 
Determinants of Multi Drug Resistant 
Tuberculosis in Surakarta. 
 
SUBJECTS AND METHOD 
1. Study design 
This was a case control study. The study 
was conducted in Dr. Moewardi hospital 
and BBKPM Surakarta, from September to 
November 2017.  
2. Population and sample 
The target population was all tuberculosis 
and MDR-TB patients. The case population 
was MDR-TB patients in Dr. Moewardi 
hospital. While the control population was 
tuberculosis patients in BBKPM Surakarta. 
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The sampling technique was fixed 
disease sampling with a large sample of 304 
research subjects using a ratio of 1: 3. The 
number of case samples was 76 MDR-TB 
patients and the control samples were 228 
tuberculosis patients. 
The inclusion criteria were subjects 
aged ≥15 years old and able to fill the 
questionnaire well. While the exclusion 
criteria of patients were those who 
experience psychiatric disorders. 
3. Study variables 
The independent variables were family 
income, depression, drug side effects, drug 
taking advisor, adherence, age, comorbidity 
and the dependent variable was MDR-TB. 
4. Operational definition of variables 
MDR-TB was defined as tuberculosis 
patients diagnosed with MDR-TB because 
Mycobacterium tuberculosis is resistant to 
two first-line anti-tuberculosis drugs 
namely rifampicin and isoniazid, and the 
measurement tool is X-pert MTB / RIF 
measurements in medical records. The 
measurement scale was categorical, coded 0 
for no MDR TB and 1 for MDR TB. 
Drug side effect was defined as the 
reaction of drug as a result of the treatment 
of tuberculosis. The data were collected by 
questionnaire. The measurement scale was 
categorical, coded 0 for no drug side effect 
and 1 for drug side effect. 
The drug taking advisor support was 
defined a person who is in charge of 
ensuring regularity or medication adhe-
rence during the patient's treatment period. 
The data were collected by questionnaire. 
The measurement scale was categorical, 
coded 0 for weak support and 1 for strong 
support. 
Depression was defined an emotional 
disturbance in patients where patients 
experience panic, stress, irritability, and 
fear. The data were collected by question-
naire. The measurement scale was conti-
nuous, but for the purpose of data analysis, 
it was transformed into dichotomous, 
coded 0 for low stress and 1 for high stress. 
Drug taking adherence was defined as 
a condition that describes patient obe-
dience in taking the appropriate medi-
cations based on health personnel instruc-
tion. The data were collected by question-
naire. The measurement scale was conti-
nuous, but for the purpose data analysis, 
transformed into dichotomous, coded 0 for 
drug taking irregularly and 1 for drug taking 
regularly.   
Family income was defined as the 
average income during the last 6 months as 
a result of the economic process or 
cumulative economic resources of the 
whole family members (husband, wife, and 
children). The data were collected by 
questionnaire. The measurement scale was 
continuous, but for the purpose data 
analysis, transformed into dichotomous, 
coded 0 for low family income and 1 for 
high family income. 
Age was defined as the age of the 
subjects from the birth to the time the study 
was conducted. The data were collected by 
questionnaire. The measurement scale was 
continuous, but for the purpose data 
analysis, transformed into dichotomous, 
coded 0 for younger age and 1 for older age. 
Comorbidity was defined as the 
presence of one or more other diseases that 
accompanied tuberculosis. The data were 
collected by questionnaire. The measure-
ment scale was categorical, coded 0 for 
without co-morbidity and 1 for with co-
morbidity. 
5. Data analysis 
The data analysis of the study used path 
analysis to determine the magnitude of the 
influence of variables, either the directly or 
indirect influences. The pathway analysis 
steps are model specification, model 
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identification, model conformity, parameter 
estimation and model respesification. 
6. Research Ethics 
The research ethical clearance was granted 
from the Research Ethics Committee at Dr. 
Moewardi Hospital, Surakarta, Central 
Java, Indonesia. Research ethics included 
issues such as informed consent, anony-
mity, confidentiality, and ethical clearance. 
 
RESULTS 
1. Sample Characteristics 
Table 1 shows the sample characteristics. As 
many as 137 study subjects (85.1%) were 
smoker.  
The characteristics of subjects in 
relation to alcohol habit, in the case group, 
almost all subjects did not have a habit of 
alcohol (58 subjects/71.1%). This is similar 
to the control group with 195 subjects 
(85.5%). 
The last characteristic is related to the 
tuberculosis contact. Most of the subjects 
did not know about tuberculosis contacts 
(58 subjects /76.3%) in the case group. 
Then, in the control group, almost all  
subjects were entirely unaware of 
tuberculosis contacts (205 subjects/89.9%).  
Table 1. The Distribution of Research Subjects  
No Characteristics 
Case Control 
N % N % 
1. Gender     
 Male 50 29.1 122 70.9 
 Female 26 19.7 106 80.3 
2. Education     
 Low  43 28.7 107 71.3 
 High 33 21.4 121 78.6 
3. Occupation     
 Working at house 13 19.4 54 80.6 
 Working outside the house 63 26.6 174 73.4 
4. Marital Status     
 Unmarried  11 21.6 40 78.4 
 Married 65 25.7 188 74.3 
5. Smoking     
 Smoking 52 36.4 91 63.6 
 Not smoking 24 14.9 137 85.1 
6. Alcohol     
 Alcohol 22 40.0 33 60.0 
 No Alcohol 54 21.7 195 78.3 
7. Contact     
 Contact 18 43.9 23 56.1 
 No Contact 58 22.1 205 77.9 
 
2. Pathway Analysis  
The results of the study were analyzed 
using STATA 13. The steps of pathway 
analysis were model specifications, model 
identification, parameter estimation and 
model respesification. The number of 
measured variables was 8, endogenous 
variables (4), and exogenous variables (4). 
So, the degree of freedom (df) was 20. 
Then, it can be concluded that df was over 
identified which means  that  the path 
analysis can be done.  
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Figure 2. Structural Model with Estimate 
The structural model with estimates shown 
in Figure 2 and the results of the analysis of 
the biopsychosocial pathways of MDR-TB 
were presented in Table 3. The models in 
this study were in accordance with the 
sample data as indicated by the saturation 
model and also the regression coefficients 
of more than zero and statistically 
significant, it is not necessary to recreate 
the path analysis model because it has 
obtained the model according to the sample 
data. 
Table 3. The result of path analysis on the biopsychosocial determinant of Multi 
Drug Resistant Tuberculosis 
Dependent 
Variabel  
 
Independent  
Variable 
b  
95% CI 
p Lower  
Limit 
Upper 
Limit  
Direct Effect       
MDR-TB  Drug taking (adherence) -1.7 -2.23 -1.06 0.001 
  Comorbidities 1.5 0.76 2.30 0.001 
Indirect Effect       
Adherence  Drug Side Effects -1.5 -2.10 -0.89 0.001 
  Drug taking advisor 2.5 1.84 3.07 0.001 
  Depression -1.7 -2.60 -0.79 0.001 
Depresi  Family income -1.1 -2.04 -0.23 0.014 
  Drug Side Effects 0.7 -0.14 1.31 0.055 
Comorbidities  Age 0.86 0.12 1.61 0.022 
N observation      = 304     
Log Likelihood= -508.40     
 
Table 3 shows the result of path 
analysis on the biopsychosocial determi-
nant of Multi Drug Resistant Tuberculosis. 
Table 3 shows that adherence in drug 
taking (b= -1.7; 95% CI = -2.23 to -1.07; p = 
0.001) decreased the risk of MDR-TB 
occurrence. 
Comorbidities increased the risk of 
MDR-TB occurrence (b = 1.5; 95% CI = 
0.76 to 2.30; p = 0.001). 
Severe depression (b = -1.7; 95% CI = 
-2.60 to -0.79; p = 0.001) and drug taking 
effect (b = -1.5; 95% CI = -2.10 to -0.86; p = 
0.001) lowered the drug taking adherence.  
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Support from drug taking advisor (b = 
2.5; 95% CI = 1.84 to 3.06; p = 0.001) 
improved the drug taking adherence.                                                                                                                                                                                                                                                                                                                                                                    
High family income decreased 
depression (b = -1.1; 95% CI = -2.04 to -
0.23; p = 0.014). 
Drug side effect increased depression 
(b= 0.65; 95% CI= -0.14 to 1.13; p = 0.055). 
Aged ≥40 years increased the likely-
hood of comorbidity (b = 0.87; 95% CI= 
0.12 to 1.61; p = 0.022).  
DISCUSSION 
1. The association between drug 
taking adherence and MDR-TB 
The result of this study showed that drug-
taking adherence decreased the risk of 
MDR-TB. This study is supported by 
Cuevas and Pe (2015), it is showed that 
patients who had low adherence during 
treatment would increase the risk of MDR-
TB by 2 times compared to the patients 
with high adherence to tuberculosis. The 
mechanism of MDR-TB occurrence is 
associated to drug failure in affecting the 
germs, or germs that do not absorb OAT. 
Bhunia et al. (2015) explains that the 
behavioral changing from sensitive to 
resistant due to lack of treatment usually 
occurs within a few weeks after the start of 
treatment with different time of the 
occurrence of resistance in each individual. 
Patients' obedience in the treatment greatly 
affects the success of treatment. The result 
of this study showed that MDR-TB is more 
prevalent in subjects of non-adherence to 
treatment than the subjects who are 
obedient in doing the treatment. Fagundez 
et al. (2016) explained that irregular follow-
up of tuberculosis causes a person to have 3 
times higher risk for MDR-TB than a 
patient who conducts the follow up 
routinely, this is in line with a study by 
Aderita Aderita et al. (2016) which showed 
that low-compliance tuberculosis patients 
had 4 times higher risk for MDR-TB.  
2. The association between comorbi-
dity and MDR-TB 
The result of this study showed that 
comorbidity increase the risk of MDR-TB. 
Diabetes mellitus (DM) is one of the most 
common comorbidities in tuberculosis 
cases (Magee et al., 2013). Navarro et al. 
(2015) explains that type 2 of DM 
comorbidities in TB cases leads to a 
decrease in the immune system, which is 
associated with poor blood sugar control, 
leading to impaired phagocytosis, chemo-
taxis, reactive oxygen species (ROS), and 
Th17 cell function. In addition, Baghaei et al. 
(2015) stated that the immune response 
disorders in TB patients with DM may 
increase the risk of resistant strains of 
infection, and it leads to MDR-TB. 
Based on the research by Mohd et al. 
(2015), it is showed that assessing the 
conversion in TB patients with DM after 
two to three months of TB therapy had 7 
times higher risk for no convention. The 
possibility of more severe infections, more 
mycobacterial charges, longer convention 
times, and longer treatment in TB patients 
with DM are more likely to be resistant to 
TB. According to Viswanathan et al. (2014), 
BTA smear in patients with DM remained 
positive in the second month of treatment, 
it is an important risk factor for the 
transmission of resistance. 
WHO describes the association of TB 
and DM is that the patients have 4 times 
higher risk of death, plasma OAT concen-
trations lower than non-DM patients, 
therefore, it leads to the risk of treatment 
failure (OAT resistance) and poor glycemic 
control which can interfere the DM 
treatment through drug interactions, and 
the disruption of certain OAT activities 
(Ministry of Health, 2015). 
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3. The association between depress-
ion and MDR-TB through drug 
taking adherence  
The result of this study showed that 
depression increase the risk of MDR-TB. 
Depression can affect the disobedience of 
treatment, the depression can increase the 
risk of morbidity and mortality as a result 
of TB disease (Duko et al., 2015). Early 
diagnosis of TB disease becomes one of the 
stressors that cause psychological disorders 
especially depression and become one of 
the factors that can affect the treatment 
process (Pachi et al., 2013). Depression 
experienced by tuberculosis sufferers often 
causes the obstruction in the treatment 
process. The causes of increased depression 
are associated with misconceptions about 
disease and long treatment (Peddireddy, 
2016). Depression that occurs will affect the 
decrease of body resistance to infection and 
affect the adherence of tuberculosis 
patients in doing tuberculosis treatment 
process, therefore, it slows the healing 
process and increases the risk of MDR-TB 
(Theron et al., 2015).  
4. The association betwen drug 
taking advisor and MDR-TB 
through adherence  
DOTS program is used as an effort to 
control tuberculosis to ensure short-term 
treatment of patients can be resolved 
properly, in addition, DOTS program can 
affect the drug-taking adherence (Ministry 
of Health, 2014). One of the DOTS com-
ponents is the OAT treatment with direct 
supervision/DSC (Vijay et al., 2010). Based 
on the research by Septia et al. (2013) it can 
be seen that big support from DSC has an 
effect on the enhancement of adherence. He 
(2016) explained that motivation and 
support from DSC can help in increasing 
the willingness of tuberculosis patients to 
recover by doing the treatment regularly 
until it is done. 
Routine Follow-up  is necessary to 
maintain the regularity in taking anti-
tuberculosis drugs, it is necessary for DSC 
to always monitor the treatment of tuber-
culosis patients (Akshata and Chakra-
barthy, 2016), besides that, if tuberculosis 
patients do the treatment regularly, it will 
reduce the risk of increasing the disease 
and prevent the transmission of tuber-
culosis disease to others (Thi et al., 2015).  
5. The association between drug side 
effect and MDR-TB through drug 
taking adherence 
The result of this study showed that DSE 
increase the risk of MDR-TB. According to 
Zhang et al. (2016), DSE affects medication 
adherence and impacts on drop out 
treatment. Woimo et al. (2017) stated that 
the lower the side effects that appear the 
higher the medication adherence. In 
addition, the treatment period that takes a 
long time and it leads to DSE, therefore, it 
causes the patient to stop taking the 
medicine (Gao et al., 2016). 
6. The association between family 
income and MDR-TB through 
depression and adherence   
The result of this study showed that family 
income decrease the risk of MDR-TB 
through depression and adherence. 
According to a study by Liu et al. (2015), it 
is stated that social economy becomes one 
of the factors that influence the tuber-
culosis. Another problem that occurs in the 
case of tuberculosis other than death is the 
fundamental problem which is economic 
problems both from government and indi-
viduals, therefore the decrease of produc-
tivity in tuberculosis sufferer becomes a 
problem that need to be solved.  
Financial life is highly dependent on 
someone's ability to work. If she/he is no 
longer productive and she/he has physical 
weakness caused by tuberculosis disease, it 
can lead to decreased work productivity 
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(Ambaw et al., 2015). Depression in 
tuberculosis patients is also associated with 
many factors, such as age, sex, 
socioeconomic status, changes in social 
relations and stigmatization of tuberculosis 
(Koyanagi et al., 2017). Economic 
problems, stigma and social support 
become one of the factors that affect the 
depression in patients with tuberculosis 
(Duko et al., 2015). Thomas et al. (2016) 
stated that risk factors that affect the 
development of various psychiatric dis-
orders is related to low socioeconomic 
status. This in accordance with the results 
of this study which indicates that family 
income increases the risk of MDR-TB 
through depression. 
7. The association between drug side 
effect and MDR-TB through 
depression and adherence  
The result of this study showed that DSE 
increase the risk of MDR-TB through 
depression and adherence. WHO defines 
ADRs as response to a drug, unintention-
ally or undesirably and occurs at doses that 
commonly used for the prevention, diag-
nosis or treatment of disease (Koyanagi et 
al., 2017). The high prevalence of psychia-
tric problems, especially depression as well 
as the presence of psychological reactions 
related to the perception of disease shows 
that psychological complications have a 
side effect of tuberculosis treatment (Farazi 
et al., 2014). One of the side effects 
obtained by tuberculosis treatment is the 
physical effects that cause the disruption of 
the work and or may affect the social role of 
the sufferer (Sulehri et al., 2012).  
Koyanagi et al. (2017) explains that the 
factors that may affect the depression in 
patients with tuberculosis are age ≥32 years 
old, male gender, tuberculosis diagnosis, 
drug side effects, low socioeconomic and 
comorbidities. Marra et al. (2014), explain-
ed that the decrease in the quality of life in 
patients with tuberculosis due to depress-
ion caused by many related aspects such as 
the existence of long-term therapy, social 
stigma associated with tuberculosis, lack of 
patient knowledge about disease, tuber-
culosis treatment process, and adverse 
reactions (drug side effects) in most 
tuberculosis patients.  
8. The association between age and 
MDR-TB through comordibity  
The result of this study showed that age 
increase the risk of MDR-TB through 
comordibityPhysiological function of the 
body will decrease at older age (≥60 years 
old) and along with the enhancement of age 
can lead to ateroklerosis and macro 
angiopathy disorder that affect the decrease 
of blood circulation so that it can lead to the 
occurrence of diseases such as diabetes 
mellitus and hypertension (Young et al., 
2009). In some studies, it has been found 
that there is a significant relationship 
between age and OAT resistance with 
higher proportion of MDR-TB  among the 
45-64 years old group, in addition, the DM 
comorbidities in older TB patients increases 
the risk of MDR-TB, because in the elderly, 
the decrease in the immune system leads to 
physical inability to fight TB bacilli thus 
increasing the risk of MDR-TB (Wahyuni et 
al., 2016). Similar to Tao et al. (2017) which 
stated that a person with diabetes and 
HIV/AIDS aged ≥45 years has 2 times 
higher risk of having MDR-TB due to a low 
immune system and decreased body 
function. Aibana et al. (2017) explains that 
the older the person, the lower the 
immunity in the body, and the older age 
groups are more exposed to other risk 
factors such as alcohol, cigarette smoke and 
infectious diseases. 
Based on the result of this study, it 
can be concluded that the risk of MDR-TB 
decrease by the enhancement of drug-
taking adherence, the support from DSC 
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and family income. The risk of MDR-TB is 
increased by the enhancement of co-
mordibity, depression, DSE and age.  
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